Pharmaron Beijing Co., Ltd.
300759
주식 순위
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
주가
$5.58
시가총액
$8.24B
변동 (1일)
-3.77%
변동 (1년)
28.36%
국가
CN
거래 Pharmaron Beijing Co., Ltd. (300759)
카테고리
Healthcare
Pharmaron Beijing Co., Ltd. (300759)의 수익
Jun 2026 기준 수익 TTM: $303.40M
Pharmaron Beijing Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $303.40M입니다. 2024년에 회사는 $286.51M의 수익을 올렸으며 이는 2023년의 수익 $259.64M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Pharmaron Beijing Co., Ltd.의 수익 기록 (2014 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $303.40M | 10.98% |
| 2025 | $273.38M | -4.58% |
| 2024 | $286.51M | 10.35% |
| 2023 | $259.64M | 7.48% |
| 2022 | $241.58M | -19.65% |
| 2021 | $300.66M | 48.87% |
| 2020 | $201.96M | 122.33% |
| 2019 | $90.84M | 59.17% |
| 2018 | $57.07M | 33.32% |
| 2017 | $42.81M | 38.55% |
| 2016 | $30.90M | 129.26% |
| 2015 | $13.48M | 188.75% |
| 2014 | $4.67M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | 1,638.58% |
US
|
|
| $-3.09B | -1,117.46% |
US
|
|
| $-4.02B | -1,423.72% |
AU
|
|
| $3.01B | 890.67% |
BE
|
|
| $1.95B | 542.93% |
NL
|
